A Selective Androgen Receptor Modulator for Hormonal Male Contraception
- 3 September 2004
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 312 (2), 546-553
- https://doi.org/10.1124/jpet.104.075424
Abstract
The recent discovery of nonsteroidal selective androgen receptor modulators (SARMs) provides a promising alternative for testosterone replacement therapies, including hormonal male contraception. The identification of an orally bioavailable SARM with the ability to mimic the central and peripheral androgenic and anabolic effects of testosterone would represent an important step toward the “male pill”. We characterized the in vitro and in vivo pharmacologic activity of (S)-3-(4-chloro-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)propionamide (C-6), a novel SARM developed in our laboratories. C-6 was identified as an androgen receptor (AR) agonist with high AR binding affinity (Ki = 4.9 nM). C-6 showed tissue-selective pharmacologic activity with higher anabolic activity than androgenic activity in male rats. The doses required to maintain the weight of the prostate, seminal vesicles, and levator ani muscle to half the size of the maximum effects (i.e., ED50) were 0.78 ± 0.06, 0.88 ± 0.1, and 0.17 ± 0.04 mg/day, respectively. As opposed to other SARMs, gonadotropin levels in C-6-treated groups were significantly lower than control values. C-6 also significantly decreased serum testosterone concentration in intact rats after 2 weeks of treatment. Marked suppression of spermatogenesis was observed after 10 weeks of treatment with C-6 in intact male rats. Pharmacokinetic studies of C-6 in male rats revealed that C-6 was well absorbed after oral administration (bioavailability 76%), with a long (6.3 h) half-life at a dose of 10 mg/kg. These studies show that C-6 mimicked the in vivo pharmacologic and endocrine effects of testosterone while maintaining the oral bioavailability and tissue-selective actions of nonsteroidal SARMs.Keywords
This publication has 24 references indexed in Scilit:
- Progress towards hormonal male contraceptionTrends in Pharmacological Sciences, 2004
- Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor ModulatorsJournal of Medicinal Chemistry, 2004
- Testicular Heat Exposure Enhances the Suppression of Spermatogenesis by Testosterone in Rats: The "Two-Hit" Approach to Male Contraceptive DevelopmentEndocrinology, 2000
- Discovery of Nonsteroidal AndrogensBiochemical and Biophysical Research Communications, 1998
- ICI 176,334: A NOVEL NON–STEROIDAL, PERIPHERALLY SELECTIVE ANTIANDROGENJournal of Endocrinology, 1987
- Effect of testosterone oenanthate on spermatogenesis and serum testosterone concentrations in adult miceReproduction, 1986
- Inhibition of Luteinizing Hormone (LH)-Releasing Hormone-Induced Secretion of LH in Rat Anterior Pituitary Cell Culture by Testosterone without Conversion to 5α-DihydrotestosteroneEndocrinology, 1984
- Endogenous Antispermatogenic Agents: Prospects for Male ContraceptionAnnual Review of Pharmacology and Toxicology, 1978
- INHIBITION AND MAINTENANCE OF SPERMATOGENESIS IN RATS IMPLANTED WITH POLYDIMETHYLSILOXANE CAPSULES CONTAINING VARIOUS ANDROGENSJournal of Endocrinology, 1974
- Effect of Gonadal Steroids on the Response to LH-RH in Intact and Castrated Male Rats*Endocrinology, 1974